Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer

Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal Cancer is a phase 2, interventional study registered as NCT04109755 by University Hospital, Geneva, with a registry enrolment figure of 25 participants, started 2020-06-02 and due to reach its primary completion in 2022-06. Interventions recorded: Pembrolizumab. Conditions listed: Rectum Cancer; Rectal Cancer. Primary outcome: Tumour regression grade. Colorectal eligibility wording from the registry: "* Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of rectal adenocarcinoma will be enrolled in this study". Sites: Switzerland. No results are recorded here; the registry entry is the source.